市場調査レポート

商品コード

1445529

脳腫瘍の世界市場の評価：薬剤・治療法・適応症・エンドユーザー・流通チャネル・地域別の機会および予測 (2017～2031年)

Brain Cancer Market Assessment, By Drug, By Therapy, By Indication, By End-user, By Distribution Channel, By Region, Opportunities and Forecast, 2017-2031F

出版日: 2024年03月07日 | 発行: Market Xcel - Markets and Data

| ページ情報: 英文 230 Pages | 納期: 3～5営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　詳細はお問い合わせください。

価格

PDF & Excel Printable (Single User License)

USD 4,500 707,130円

レポートPDFを1名の方がご利用頂けるライセンスです。レポートPDFのパスワード保護はありません。PDF内のテキスト等のコピー＆ペーストは可能です。印刷は無制限で可能です。Excelのデータがライセンスに含まれています。

PDF & Excel Printable (Corporate License)

USD 5,700 895,698円

レポートPDFを企業の１カ国の拠点のすべての方がご利用頂けるライセンスです。レポートPDFのパスワード保護はありません。PDF内のテキスト等のコピー＆ペーストは可能ですが、企業内部での利用に限定されます。ご利用に際しては、あらかじめ出版社の許諾を得る必要があります。詳細はお問合せください。印刷は可能です。Excelのデータがライセンスに含まれています。

PDF & Excel Printable (Custom Research License)

USD 8,200 1,288,548円

レポートPDFを企業の１カ国の拠点のすべての方がご利用頂けるライセンスです。レポートPDFのパスワード保護はありません。PDF内のテキスト等のコピー＆ペーストは可能です。印刷は無制限で可能です。Excelのデータがライセンスに含まれています。アナリストアワー100時間が含まれており、レポートのカスタマイズなどにご利用いただけます。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=157.14円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

世界の脳腫瘍の市場規模は、2024年から2031年の予測期間中にCAGR 10.03％を記録し、2023年の25億1,000万米ドルから、2031年には53億9,000万米ドルの規模に成長すると予測されています。

世界のさまざまな地域でこの疾患の有病率が増加しており、これが市場の成長を後押しすると予想されています。

American Cancer Societyの推計によると、米国では2023年に約25,400例の脊髄または脳の悪性腫瘍が診断されています。これらの診断例のうち、10,980例が女性、14,420例が男性と診断される見込みです。脊髄腫瘍や脳腫瘍で死亡する人はおよそ18,760人と推定されます。小児および成人の神経疾患に対する意識の高まりが、市場に有利な成長機会をもたらしています。脳腫瘍を発症する可能性を高めるさまざまな危険因子には、ウイルス、アレルゲン、感染症、N-ニトロソ化合物への曝露、頭部外傷や発作などが含まれます。

拡大するR&D活動

脊髄腫瘍と脳腫瘍を対象としたさまざまな研究活動では、効果的な治療法に伴うさまざまな毒性作用の軽減、癌の根本的な原因の特定、新規治療法や送達方法の決定などに取り組んでいます。例えば、2023年には、the University of Texas at DallasとUT Southwestern Medical Centerの研究チームが、金ナノ粒子を用いて血液脳関門から薬剤を送達する方法を開発しました。この技術は、一般的な脳腫瘍の一種である膠芽腫の治療において、臨床試験で良好な結果を示しました。このドラッグデリバリー法は、血管をターゲットにした金ナノ粒子と薬剤を共配合し、それを血流に注入するものです。この実験では、肺癌、卵巣癌、乳癌の治療用化学療法薬としてパクリタキセルが使用されました。

小児・成人とも増加する罹患率

American Cancer Societyによると、脊髄および脳腫瘍は小児に2番目に多い癌であり、脊髄腫瘍と脳腫瘍は、小児癌の約4件に1件を占めています。脳腫瘍と診断された小児のほぼ4人に3人は、診断を受けてから少なくとも5年は生存しています。そのため、小児に対する癌治療薬の効果を明らかにするためにさまざまな研究が行われており、これが脳腫瘍市場の成長にさらにつながっています。

当レポートでは、世界の脳腫瘍の市場を調査し、市場の定義と概要、市場規模の推移・予測、各種区分・地域別の詳細分析、産業構造、市場成長への影響因子の分析、ケーススタディ、競合情勢、主要企業のプロファイルなどをまとめています。

市場規模・予測
薬剤別
- カルムスチン
- シスプラチン
- ベバシズマブ
- テモゾロミド
- ベルズティファン
- その他
治療法別
- 化学療法
- 標的療法
- 免疫療法
- その他
適応症別
- 下垂体腫瘍
- 神経膠腫
- 髄膜腫
- その他
エンドユーザー別
- 病院
- 癌センター
- 診断ラボ
流通チャネル別
- 病院薬局
- 小売薬局
- オンライン薬局
地域別
- 北米
- 欧州
- アジア太平洋
- 南米
- 中東・アフリカ
企業別市場シェア

第5章世界の脳腫瘍市場の展望：地域別

北米
欧州
アジア太平洋
南米
中東・アフリカ

第6章市場マッピング

薬剤別
治療法別
適応症別
エンドユーザー別
流通チャネル別
地域別

第7章マクロ環境と産業構造

需要供給分析
輸出入分析
バリューチェーン分析
PESTEL分析
ポーターのファイブフォース分析

第8章市場力学

成長促進要因
成長抑制要因（課題、抑制要因）

第9章規制の枠組みとイノベーション

特許の情勢
規制当局の承認
イノベーション・新興技術

第10章主要企業の情勢

市場リーダー上位5社の競合マトリックス
市場リーダー上位5社の市場収益分析
M&A・ジョイントベンチャー (該当する場合)
SWOT分析 (参入5社)

第11章価格分析

第12章ケーススタディ

第13章主要企業の見通し

Pfizer, Inc.
F. Hoffmann-La Roche Ltd.
Bayer AG
Bristol-Myers Squibb Company
Novartis AG
Johnson & Johnson Inc.
Dr. Reddy's Laboratories Ltd.
Amgen Inc.
EpicentRx, Inc.
Siemens Healthineer

第14章戦略的提言

第15章当社について・免責事項

図表

List of Tables

Table 1. Pricing Analysis of Products from Key Players
Table 2. Competition Matrix of Top 5 Market Leaders
Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

Figure 1. Global Brain Cancer Market, By Value, In USD Billion, 2017-2031F
Figure 2. Global Brain Cancer Market, By Volume, In Million Units, 2017-2031F
Figure 3. Global Brain Cancer Market Share (%), By Drug, 2017-2031F
Figure 4. Global Brain Cancer Market Share (%), By Therapy, 2017-2031F
Figure 5. Global Brain Cancer Market Share (%), By Indication, 2017-2031F
Figure 6. Global Brain Cancer Market Share (%), By End-user, 2017-2031F
Figure 7. Global Brain Cancer Market Share (%), By Distribution Channel, 2017-2031F
Figure 8. Global Brain Cancer Market Share (%), By Region, 2017-2031F
Figure 9. North America Brain Cancer Market, By Value, In USD Billion, 2017-2031F
Figure 10. North America Brain Cancer Market, By Volume, In Million Units, 2017-2031F
Figure 11. North America Brain Cancer Market Share (%), By Drug, 2017-2031F
Figure 12. North America Brain Cancer Market Share (%), By Therapy, 2017-2031F
Figure 13. North America Brain Cancer Market Share (%), By Indication, 2017-2031F
Figure 14. North America Brain Cancer Market Share (%), By End-user, 2017-2031F
Figure 15. North America Brain Cancer Market Share (%), By Distribution Channel, 2017-2031F
Figure 16. North America Brain Cancer Market Share (%), By Country, 2017-2031F
Figure 17. United States Brain Cancer Market, By Value, In USD Billion, 2017-2031F
Figure 18. United States Brain Cancer Market, By Volume, In Million Units, 2017-2031F
Figure 19. United States Brain Cancer Market Share (%), By Drug, 2017-2031F
Figure 20. United States Brain Cancer Market Share (%), By Therapy, 2017-2031F
Figure 21. United States Brain Cancer Market Share (%), By Indication, 2017-2031F
Figure 22. United States Brain Cancer Market Share (%), By End-user, 2017-2031F
Figure 23. United States Brain Cancer Market Share (%), By Distribution Channel, 2017-2031F
Figure 24. Canada Brain Cancer Market, By Value, In USD Billion, 2017-2031F
Figure 25. Canada Brain Cancer Market, By Volume, In Million Units, 2017-2031F
Figure 26. Canada Brain Cancer Market Share (%), By Drug, 2017-2031F
Figure 27. Canada Brain Cancer Market Share (%), By Therapy, 2017-2031F
Figure 28. Canada Brain Cancer Market Share (%), By Indication, 2017-2031F
Figure 29. Canada Brain Cancer Market Share (%), By End-user, 2017-2031F
Figure 30. Canada Brain Cancer Market Share (%), By Distribution Channel, 2017-2031F
Figure 31. Mexico Brain Cancer Market, By Value, In USD Billion, 2017-2031F
Figure 32. Mexico Brain Cancer Market, By Volume, In Million Units, 2017-2031F
Figure 33. Mexico Brain Cancer Market Share (%), By Drug, 2017-2031F
Figure 34. Mexico Brain Cancer Market Share (%), By Therapy, 2017-2031F
Figure 35. Mexico Brain Cancer Market Share (%), By Indication, 2017-2031F
Figure 36. Mexico Brain Cancer Market Share (%), By End-user, 2017-2031F
Figure 37. Mexico Brain Cancer Market Share (%), By Distribution Channel, 2017-2031F
Figure 38. Europe Brain Cancer Market, By Value, In USD Billion, 2017-2031F
Figure 39. Europe Brain Cancer Market, By Volume, In Million Units, 2017-2031F
Figure 40. Europe Brain Cancer Market Share (%), By Drug, 2017-2031F
Figure 41. Europe Brain Cancer Market Share (%), By Therapy, 2017-2031F
Figure 42. Europe Brain Cancer Market Share (%), By Indication, 2017-2031F
Figure 43. Europe Brain Cancer Market Share (%), By End-user, 2017-2031F
Figure 44. Europe Brain Cancer Market Share (%), By Distribution Channel, 2017-2031F
Figure 45. Europe Brain Cancer Market Share (%), By Country, 2017-2031F
Figure 46. Germany Brain Cancer Market, By Value, In USD Billion, 2017-2031F
Figure 47. Germany Brain Cancer Market, By Volume, In Million Units, 2017-2031F
Figure 48. Germany Brain Cancer Market Share (%), By Drug, 2017-2031F
Figure 49. Germany Brain Cancer Market Share (%), By Therapy, 2017-2031F
Figure 50. Germany Brain Cancer Market Share (%), By Indication, 2017-2031F
Figure 51. Germany Brain Cancer Market Share (%), By End-user, 2017-2031F
Figure 52. Germany Brain Cancer Market Share (%), By Distribution Channel, 2017-2031F
Figure 53. France Brain Cancer Market, By Value, In USD Billion, 2017-2031F
Figure 54. France Brain Cancer Market, By Volume, In Million Units, 2017-2031F
Figure 55. France Brain Cancer Market Share (%), By Drug, 2017-2031F
Figure 56. France Brain Cancer Market Share (%), By Therapy, 2017-2031F
Figure 57. France Brain Cancer Market Share (%), By Indication, 2017-2031F
Figure 58. France Brain Cancer Market Share (%), By End-user, 2017-2031F
Figure 59. France Brain Cancer Market Share (%), By Distribution Channel, 2017-2031F
Figure 60. Italy Brain Cancer Market, By Value, In USD Billion, 2017-2031F
Figure 61. Italy Brain Cancer Market, By Volume, In Million Units, 2017-2031F
Figure 62. Italy Brain Cancer Market Share (%), By Drug, 2017-2031F
Figure 63. Italy Brain Cancer Market Share (%), By Therapy, 2017-2031F
Figure 64. Italy Brain Cancer Market Share (%), By Indication, 2017-2031F
Figure 65. Italy Brain Cancer Market Share (%), By End-user, 2017-2031F
Figure 66. Italy Brain Cancer Market Share (%), By Distribution Channel, 2017-2031F
Figure 67. United Kingdom Brain Cancer Market, By Value, In USD Billion, 2017-2031F
Figure 68. United Kingdom Brain Cancer Market, By Volume, In Million Units, 2017-2031F
Figure 69. United Kingdom Brain Cancer Market Share (%), By Drug, 2017-2031F
Figure 70. United Kingdom Brain Cancer Market Share (%), By Therapy, 2017-2031F
Figure 71. United Kingdom Brain Cancer Market Share (%), By Indication, 2017-2031F
Figure 72. United Kingdom Brain Cancer Market Share (%), By End-user, 2017-2031F
Figure 73. United Kingdom Brain Cancer Market Share (%), By Distribution Channel, 2017-2031F
Figure 74. Russia Brain Cancer Market, By Value, In USD Billion, 2017-2031F
Figure 75. Russia Brain Cancer Market, By Volume, In Million Units, 2017-2031F
Figure 76. Russia Brain Cancer Market Share (%), By Drug, 2017-2031F
Figure 77. Russia Brain Cancer Market Share (%), By Therapy, 2017-2031F
Figure 78. Russia Brain Cancer Market Share (%), By Indication, 2017-2031F
Figure 79. Russia Brain Cancer Market Share (%), By End-user, 2017-2031F
Figure 80. Russia Brain Cancer Market Share (%), By Distribution Channel, 2017-2031F
Figure 81. Netherlands Brain Cancer Market, By Value, In USD Billion, 2017-2031F
Figure 82. Netherlands Brain Cancer Market, By Volume, In Million Units, 2017-2031F
Figure 83. Netherlands Brain Cancer Market Share (%), By Drug, 2017-2031F
Figure 84. Netherlands Brain Cancer Market Share (%), By Therapy, 2017-2031F
Figure 85. Netherlands Brain Cancer Market Share (%), By Indication, 2017-2031F
Figure 86. Netherlands Brain Cancer Market Share (%), By End-user, 2017-2031F
Figure 87. Netherlands Brain Cancer Market Share (%), By Distribution Channel, 2017-2031F
Figure 88. Spain Brain Cancer Market, By Value, In USD Billion, 2017-2031F
Figure 89. Spain Brain Cancer Market, By Volume, In Million Units, 2017-2031F
Figure 90. Spain Brain Cancer Market Share (%), By Drug, 2017-2031F
Figure 91. Spain Brain Cancer Market Share (%), By Therapy, 2017-2031F
Figure 92. Spain Brain Cancer Market Share (%), By Indication, 2017-2031F
Figure 93. Spain Brain Cancer Market Share (%), By End-user, 2017-2031F
Figure 94. Spain Brain Cancer Market Share (%), By Distribution Channel, 2017-2031F
Figure 95. Turkey Brain Cancer Market, By Value, In USD Billion, 2017-2031F
Figure 96. Turkey Brain Cancer Market, By Volume, In Million Units, 2017-2031F
Figure 97. Turkey Brain Cancer Market Share (%), By Drug, 2017-2031F
Figure 98. Turkey Brain Cancer Market Share (%), By Therapy, 2017-2031F
Figure 99. Turkey Brain Cancer Market Share (%), By Indication, 2017-2031F
Figure 100. Turkey Brain Cancer Market Share (%), By End-user, 2017-2031F
Figure 101. Turkey Brain Cancer Market Share (%), By Distribution Channel, 2017-2031F
Figure 102. Poland Brain Cancer Market, By Value, In USD Billion, 2017-2031F
Figure 103. Poland Brain Cancer Market, By Volume, In Million Units, 2017-2031F
Figure 104. Poland Brain Cancer Market Share (%), By Drug, 2017-2031F
Figure 105. Poland Brain Cancer Market Share (%), By Therapy, 2017-2031F
Figure 106. Poland Brain Cancer Market Share (%), By Indication, 2017-2031F
Figure 107. Poland Brain Cancer Market Share (%), By End-user, 2017-2031F
Figure 108. Poland Brain Cancer Market Share (%), By Distribution Channel, 2017-2031F
Figure 109. South America Brain Cancer Market, By Value, In USD Billion, 2017-2031F
Figure 110. South America Brain Cancer Market, By Volume, In Million Units, 2017-2031F
Figure 111. South America Brain Cancer Market Share (%), By Drug, 2017-2031F
Figure 112. South America Brain Cancer Market Share (%), By Therapy, 2017-2031F
Figure 113. South America Brain Cancer Market Share (%), By Indication, 2017-2031F
Figure 114. South America Brain Cancer Market Share (%), By End-user, 2017-2031F
Figure 115. South America Brain Cancer Market Share (%), By Distribution Channel, 2017-2031F
Figure 116. South America Brain Cancer Market Share (%), By Country, 2017-2031F
Figure 117. Brazil Brain Cancer Market, By Value, In USD Billion, 2017-2031F
Figure 118. Brazil Brain Cancer Market, By Volume, In Million Units, 2017-2031F
Figure 119. Brazil Brain Cancer Market Share (%), By Drug, 2017-2031F
Figure 120. Brazil Brain Cancer Market Share (%), By Therapy, 2017-2031F
Figure 121. Brazil Brain Cancer Market Share (%), By Indication, 2017-2031F
Figure 122. Brazil Brain Cancer Market Share (%), By End-user, 2017-2031F
Figure 123. Brazil Brain Cancer Market Share (%), By Distribution Channel, 2017-2031F
Figure 124. Argentina Brain Cancer Market, By Value, In USD Billion, 2017-2031F
Figure 125. Argentina Brain Cancer Market, By Volume, In Million Units, 2017-2031F
Figure 126. Argentina Brain Cancer Market Share (%), By Drug, 2017-2031F
Figure 127. Argentina Brain Cancer Market Share (%), By Therapy, 2017-2031F
Figure 128. Argentina Brain Cancer Market Share (%), By Indication, 2017-2031F
Figure 129. Argentina Brain Cancer Market Share (%), By End-user, 2017-2031F
Figure 130. Argentina Brain Cancer Market Share (%), By Distribution Channel, 2017-2031F
Figure 131. Asia-Pacific Brain Cancer Market, By Value, In USD Billion, 2017-2031F
Figure 132. Asia-Pacific Brain Cancer Market, By Volume, In Million Units, 2017-2031F
Figure 133. Asia-Pacific Brain Cancer Market Share (%), By Drug, 2017-2031F
Figure 134. Asia-Pacific Brain Cancer Market Share (%), By Therapy, 2017-2031F
Figure 135. Asia-Pacific Brain Cancer Market Share (%), By Indication, 2017-2031F
Figure 136. Asia-Pacific Brain Cancer Market Share (%), By End-user, 2017-2031F
Figure 137. Asia- Pacific Brain Cancer Market Share (%), By Distribution Channel, 2017-2031F
Figure 138. Asia-Pacific Brain Cancer Market Share (%), By Country, 2017-2031F
Figure 139. India Brain Cancer Market, By Value, In USD Billion, 2017-2031F
Figure 140. India Brain Cancer Market, By Volume, In Million Units, 2017-2031F
Figure 141. India Brain Cancer Market Share (%), By Drug, 2017-2031F
Figure 142. India Brain Cancer Market Share (%), By Therapy, 2017-2031F
Figure 143. India Brain Cancer Market Share (%), By Indication, 2017-2031F
Figure 144. India Brain Cancer Market Share (%), By End-user, 2017-2031F
Figure 145. India Brain Cancer Market Share (%), By Distribution Channel, 2017-2031F
Figure 146. China Brain Cancer Market, By Value, In USD Billion, 2017-2031F
Figure 147. China Brain Cancer Market, By Volume, In Million Units, 2017-2031F
Figure 148. China Brain Cancer Market Share (%), By Drug, 2017-2031F
Figure 149. China Brain Cancer Market Share (%), By Therapy, 2017-2031F
Figure 150. China Brain Cancer Market Share (%), By Indication, 2017-2031F
Figure 151. China Brain Cancer Market Share (%), By End-user, 2017-2031F
Figure 152. China Brain Cancer Market Share (%), By Distribution Channel, 2017-2031F
Figure 153. Japan Brain Cancer Market, By Value, In USD Billion, 2017-2031F
Figure 154. Japan Brain Cancer Market, By Volume, In Million Units, 2017-2031F
Figure 155. Japan Brain Cancer Market Share (%), By Drug, 2017-2031F
Figure 156. Japan Brain Cancer Market Share (%), By Therapy, 2017-2031F
Figure 157. Japan Brain Cancer Market Share (%), By Indication, 2017-2031F
Figure 158. Japan Brain Cancer Market Share (%), By End-user, 2017-2031F
Figure 159. Japan Brain Cancer Market Share (%), By Distribution Channel, 2017-2031F
Figure 160. Australia Brain Cancer Market, By Value, In USD Billion, 2017-2031F
Figure 161. Australia Brain Cancer Market, By Volume, In Million Units, 2017-2031F
Figure 162. Australia Brain Cancer Market Share (%), By Drug, 2017-2031F
Figure 163. Australia Brain Cancer Market Share (%), By Therapy, 2017-2031F
Figure 164. Australia Brain Cancer Market Share (%), By Indication, 2017-2031F
Figure 165. Australia Brain Cancer Market Share (%), By End-user, 2017-2031F
Figure 166. Australia Brain Cancer Market Share (%), By Distribution Channel, 2017-2031F
Figure 167. Vietnam Brain Cancer Market, By Value, In USD Billion, 2017-2031F
Figure 168. Vietnam Brain Cancer Market, By Volume, In Million Units, 2017-2031F
Figure 169. Vietnam Brain Cancer Market Share (%), By Drug, 2017-2031F
Figure 170. Vietnam Brain Cancer Market Share (%), By Therapy, 2017-2031F
Figure 171. Vietnam Brain Cancer Market Share (%), By Indication, 2017-2031F
Figure 172. Vietnam Brain Cancer Market Share (%), By End-user, 2017-2031F
Figure 173. Vietnam Brain Cancer Market Share (%), By Distribution Channel, 2017-2031F
Figure 174. South Korea Brain Cancer Market, By Value, In USD Billion, 2017-2031F
Figure 175. South Korea Brain Cancer Market, By Volume, In Million Units, 2017-2031F
Figure 176. South Korea Brain Cancer Market Share (%), By Drug, 2017-2031F
Figure 177. South Korea Brain Cancer Market Share (%), By Therapy, 2017-2031F
Figure 178. South Korea Brain Cancer Market Share (%), By Indication, 2017-2031F
Figure 179. South Korea Brain Cancer Market Share (%), By End-user, 2017-2031F
Figure 180. South Korea Brain Cancer Market Share (%), By Distribution Channel, 2017-2031F
Figure 181. Indonesia Brain Cancer Market, By Value, In USD Billion, 2017-2031F
Figure 182. Indonesia Brain Cancer Market, By Volume, In Million Units, 2017-2031F
Figure 183. Indonesia Brain Cancer Market Share (%), By Drug, 2017-2031F
Figure 184. Indonesia Brain Cancer Market Share (%), By Therapy, 2017-2031F
Figure 185. Indonesia Brain Cancer Market Share (%), By Indication, 2017-2031F
Figure 186. Indonesia Brain Cancer Market Share (%), By End-user, 2017-2031F
Figure 187. Indonesia Brain Cancer Market Share (%), By Distribution Channel, 2017-2031F
Figure 188. Philippines Brain Cancer Market, By Value, In USD Billion, 2017-2031F
Figure 189. Philippines Brain Cancer Market, By Volume, In Million Units, 2017-2031F
Figure 190. Philippines Brain Cancer Market Share (%), By Drug, 2017-2031F
Figure 191. Philippines Brain Cancer Market Share (%), By Therapy, 2017-2031F
Figure 192. Philippines Brain Cancer Market Share (%), By Indication, 2017-2031F
Figure 193. Philippines Brain Cancer Market Share (%), By End-user, 2017-2031F
Figure 194. Philippines Brain Cancer Market Share (%), By Distribution Channel, 2017-2031F
Figure 195. Middle East & Africa Brain Cancer Market, By Value, In USD Billion, 2017-2031F
Figure 196. Middle East & Africa Brain Cancer Market, By Volume, In Million Units, 2017-2031F
Figure 197. Middle East & Africa Brain Cancer Market Share (%), By Drug, 2017-2031F
Figure 198. Middle East & Africa Brain Cancer Market Share (%), By Therapy, 2017-2031F
Figure 199. Middle East & Africa Brain Cancer Market Share (%), By Indication, 2017-2031F
Figure 200. Middle East & Africa Brain Cancer Market Share (%), By End-user, 2017-2031F
Figure 201. Middle East & Africa Brain Cancer Market Share (%), By Distribution Channel, 2017-2031F
Figure 202. Middle East & Africa Brain Cancer Market Share (%), By Country, 2017-2031F
Figure 203. Saudi Arabia Brain Cancer Market, By Value, In USD Billion, 2017-2031F
Figure 204. Saudi Arabia Brain Cancer Market, By Volume, In Million Units, 2017-2031F
Figure 205. Saudi Arabia Brain Cancer Market Share (%), By Drug, 2017-2031F
Figure 206. Saudi Arabia Brain Cancer Market Share (%), By Therapy, 2017-2031F
Figure 207. Saudi Arabia Brain Cancer Market Share (%), By Indication, 2017-2031F
Figure 208. Saudi Arabia Brain Cancer Market Share (%), By End-user, 2017-2031F
Figure 209. Saudi Arabia Brain Cancer Market Share (%), By Distribution Channel, 2017-2031F
Figure 210. UAE Brain Cancer Market, By Value, In USD Billion, 2017-2031F
Figure 211. UAE Brain Cancer Market, By Volume, In Million Units, 2017-2031F
Figure 212. UAE Brain Cancer Market Share (%), By Drug, 2017-2031F
Figure 213. UAE Brain Cancer Market Share (%), By Therapy, 2017-2031F
Figure 214. UAE Brain Cancer Market Share (%), By Indication, 2017-2031F
Figure 215. UAE Brain Cancer Market Share (%), By End-user, 2017-2031F
Figure 216. UAE Brain Cancer Market Share (%), By Distribution Channel, 2017-2031F
Figure 217. South Africa Brain Cancer Market, By Value, In USD Billion, 2017-2031F
Figure 218. South Africa Brain Cancer Market, By Volume, In Million Units, 2017-2031F
Figure 219. South Africa Brain Cancer Market Share (%), By Drug, 2017-2031F
Figure 220. South Africa Brain Cancer Market Share (%), By Therapy, 2017-2031F
Figure 221. South Africa Brain Cancer Market Share (%), By Indication, 2017-2031F
Figure 222. South Africa Brain Cancer Market Share (%), By End-user, 2017-2031F
Figure 223. South Africa Brain Cancer Market Share (%), By Distribution Channel, 2017-2031F
Figure 224. By Drug Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 225. By Therapy Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 226. By Indication Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 227. By End-user Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 228. By Distribution Channel Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 229. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023

Product Code: MX11078

Global brain cancer market is projected to witness a CAGR of 10.03% during the forecast period 2024-2031, growing from USD 2.51 billion in 2023 to USD 5.39 billion in 2031F. The increasing prevalence of the disease in various regions across the globe is expected to boost the growth of the market.

As per the estimates of the American Cancer Society, approximately 25,400 malignant tumors of the spinal cord or brain have been diagnosed in the United States in 2023. Out of these diagnosed cases, 10,980 are expected to be diagnosed in females and 14,420 are expected to be diagnosed in males. It is estimated that roughly 18,760 people will die from spinal cord and brain tumors. The rising awareness about neurological diseases in both children and adults is providing lucrative growth opportunities to the market. The different risk factors that are attributed to an increased chance of developing brain tumors include exposure to viruses, allergens, infections, N-nitroso compounds, and head injuries and seizures.

Increasing efforts of various governments to combat the disease are supporting important research discoveries. Various governments are investing in researching new ways to treat, diagnose, and prevent brain cancer. For instance, the government of Canada is dedicated to the development of new treatment strategies by promoting scientific collaborations. The collaborations with organizations such as the Brain Tumor Foundation of Canada and the Brain Canada Foundation (BC) are aiding in maximizing the impact of research investments. A neurosurgeon-scientist at the University of Toronto and the University Health Network, with the help of brain cancer research funding was able to find new therapies for preventing high-risk surgical procedures and transform the clinical management of patients with brain tumors. Another partnership with the Canadian Cancer Society has united 10 research teams that aim at making life-changing breakthroughs in brain cancer.

Growing Research and Development Activities

The various research activities aimed at spinal cord and brain tumors are dedicated to reducing the different toxic effects associated with effective therapies, identifying the underlying cause of cancer, and determining novel treatments and delivery methods. For instance, in 2023, a team of researchers from the University of Texas at Dallas and UT Southwestern Medical Center developed a method to deliver medication through the blood-brain barrier, using gold nanoparticles. The technique showed positive results for the treatment of glioblastoma, a common form of brain cancer, in the clinical study. The drug delivery method relies on the co-delivery of medication with vessel-targeted gold nanoparticles, that are then injected into the bloodstream. In the experiment, paclitaxel was used by the researchers to conclude the chemotherapy drug for treating lung, ovarian, and breast cancers.

Increasing Prevalence of Disease in Both Children and Adults

According to the American Cancer Society, spinal cord and brain tumors are the second most common type of cancer in children. They account for approximately one out of four cases of cancer in children. Almost three out of four children diagnosed with brain tumors survive at least five years after receiving the diagnosis. Hence, various studies are being conducted to determine the effects of cancer-treating drugs on children, which is further leading to the brain cancer market growth.

For instance, the PIRATE study conducted by EpicentRx, Inc. aims to determine the side effects of RRx-001 in young adults and children when given together with temozolomide and irinotecan. The study aims to determine if the given combination is helpful for young adults and children with previously treated cancerous tumors.

North America is Expected to Account for Significant Market Share

North America is expected to dominate the market due to the growing prevalence of brain cancer in the United States and Canada and the increase in the emphasis on cancer research. According to the National Brain Tumor Society, approximately one million individuals are living with a brain tumor in America and 94,390 individuals are expected to receive a primary brain tumor diagnosis in 2023. The Canadian Cancer Society estimated that, in 2023, 3,200 Canadians will be diagnosed with spinal cord and brain cancer and nearly 2,500 Canadians will die amongst them. Due to the unique challenges presented by brain cancer, research and development activities are increasingly being conducted by various research institutions and market players. Currently, a study is being conducted by the University of Alabama in Birmingham to determine the safety and tolerability of novel gamma-delta T cell therapy for treating patients who recently received a diagnosis of glioblastoma.

Increasing Cases of Glioma Support Market Growth

According to the National Brain Tumor Society, glioblastoma accounts for 50.1% of all primary malignant brain tumors, and has more than 14,490 Americans, expected to receive a diagnosis of glioblastoma in 2023. According to an article published by researchers from MU School of Medicine and the University of Rochester, in May 2023, 6 out of every 100,000 people receive a diagnosis of glioma in the United States every year. Due to the increasing prevalence of glioma in different regions across the globe, research and development activities are increasing to find novel treatment solutions.

Various regulatory bodies such as the Food and Drug Administration (FDA) are providing fast-track designation to drugs that treat glioma. For instance, the FDA granted fast-track designation to the herpes simplex virus-1 (HSV-1) viral immunotherapy agent CAN-3110 as a treatment for enhancing the overall survival of patients suffering from recurrent high-grade glioma. Across all dosing levels, the findings supported the safety of CAN-3110 despite the presence of HSV1 ICP34.5 gene. CAN-3110 is a first in class oncolytic viral immunotherapy that is designed for targeting cancer cells expressing Nestin.

Hospital Pharmacies Expected to Witness Significant Growth

The longstanding trust associated with hospital pharmacies is bolstering the expansion of the segment. Drugs that are essential for treatment of brain tumor are prescribed after the receipt of diagnosis and often require hospital administration. Furthermore, the easy claim of health insurance policies across hospital pharmacies further encourages patients to purchase brain cancer-treating drugs from them. The convenience offered by hospital pharmacies coupled with the assurance of availability of quality products that are within the expiry period is further boosting the segment growth.

On the contrary, online pharmacies are anticipated to witness significant expansion over the forecast period. It is due to the availability of a wide range of benefits offered by online pharmacies including fast delivery and shipping, privacy, and discount codes and coupons. The increasing practice of purchasing medicines from legitimate and verified online pharmacies across developed countries is supporting the expansion of the segment.

Future Market Scenario (2024 - 2031F)

Increasing research and development activities and supportive government initiatives are expected to support the growth of the market over the forecast period.

In 2023, a research team at Brigham and Women's Hospital tested and developed a novel approach for assessing the working of antitumor drugs for different patients. The scientists developed drug releasing microdevices that were used for testing several drugs, however only one of them was administered to the patients. Conducting further studies will aid in determining the effectiveness of microdevices in personalized cancer treatments.

Several studies are underway to determine the effects of various drugs on both adults and children.

A study being conducted by the University of Alabama at Birmingham is expected to determine the safety and tolerability of novel gamma-delta T cell therapy for treating patients who recently received a diagnosis of glioblastoma, projected to conclude by December 2024.

Key Players Landscape and Outlook

Key participants in the brain cancer market include F. Hoffmann-La Roche Ltd., Bayer AG, Bristol-Myers Squibb Company, EpicentRx, Inc., and Siemens Healthineer. The market is expected to witness significant growth owing to rising investments by major market players in research and development activities and strategic collaborations. In 2023, the partnership between Ever Fortune and medical equipment giants Siemens Healthineers and General Electric Company (GE) was announced. Following the collaboration with the medical equipment giants, Ever Fortune is expected to focus on its expansion in the Southeast Asian market and strengthen its cooperation with major companies.

1. Research Methodology

2. Project Scope & Definitions

3. Executive Summary

4. Global Brain Cancer Market Outlook, 2017-2031F

4.1. Market Size & Forecast
- 4.1.1. By Value
- 4.1.2. By Volume
4.2. By Drug
- 4.2.1. Carmustine
- 4.2.2. Cisplatin
- 4.2.3. Bevacizumab
- 4.2.4. Temozolomide
- 4.2.5. Belzutifan
- 4.2.6. Others
4.3. By Therapy
- 4.3.1. Chemotherapy
- 4.3.2. Targeted Therapy
- 4.3.3. Immunotherapy
- 4.3.4. Others
4.4. By Indication
- 4.4.1. Pituitary
- 4.4.2. Glioma
- 4.4.3. Meningioma
- 4.4.4. Others
4.5. By End-user
- 4.5.1. Hospitals
- 4.5.2. Cancer Centers
- 4.5.3. Diagnostic Laboratories
4.6. By Distribution Channel
- 4.6.1. Hospital Pharmacy
- 4.6.2. Retail Pharmacy
- 4.6.3. Online Pharmacy
4.7. By Region
- 4.7.1. North America
- 4.7.2. South America
- 4.7.3. Europe
- 4.7.4. Asia-Pacific
- 4.7.5. Middle East & Africa
4.8. By Company Market Share (%), 2023

5. Global Brain Cancer Market Outlook, By Region, 2017-2031F

5.1. North America*
- 5.1.1. Market Size & Forecast
  - 5.1.1.1. By Value
  - 5.1.1.2. By Volume
- 5.1.2. By Drug
  - 5.1.2.1. Carmustine
  - 5.1.2.2. Cisplatin
  - 5.1.2.3. Bevacizumab
  - 5.1.2.4. Temozolomide
  - 5.1.2.5. Belzutifan
  - 5.1.2.6. Others
- 5.1.3. By Therapy
  - 5.1.3.1. Chemotherapy
  - 5.1.3.2. Targeted Therapy
  - 5.1.3.3. Immunotherapy
  - 5.1.3.4. Others
- 5.1.4. By Indication
  - 5.1.4.1. Pituitary
  - 5.1.4.2. Glioma
  - 5.1.4.3. Meningioma
  - 5.1.4.4. Others
- 5.1.5. By End-user
  - 5.1.5.1. Hospitals
  - 5.1.5.2. Cancer Centers
  - 5.1.5.3. Diagnostic Laboratories
- 5.1.6. By Distribution Channel
  - 5.1.6.1. Hospital Pharmacy
  - 5.1.6.2. Retail Pharmacy
  - 5.1.6.3. Online Pharmacy
- 5.1.7. United States*
  - 5.1.7.1. Market Size & Forecast
  - 5.1.7.1.1. By Value
  - 5.1.7.1.2. By Volume
  - 5.1.7.2. By Drug
  - 5.1.7.2.1. Carmustine
  - 5.1.7.2.2. Cisplatin
  - 5.1.7.2.3. Bevacizumab
  - 5.1.7.2.4. Temozolomide
  - 5.1.7.2.5. Belzutifan
  - 5.1.7.2.6. Others
  - 5.1.7.3. By Therapy
  - 5.1.7.3.1. Chemotherapy
  - 5.1.7.3.2. Targeted Therapy
  - 5.1.7.3.3. Immunotherapy
  - 5.1.7.3.4. Others
  - 5.1.7.4. By Indication
  - 5.1.7.4.1. Pituitary
  - 5.1.7.4.2. Glioma
  - 5.1.7.4.3. Meningioma
  - 5.1.7.4.4. Others
  - 5.1.7.5. By End-user
  - 5.1.7.5.1. Hospitals
  - 5.1.7.5.2. Cancer Centers
  - 5.1.7.5.3. Diagnostic Laboratories
  - 5.1.7.6. By Distribution Channel
  - 5.1.7.6.1. Hospital Pharmacy
  - 5.1.7.6.2. Retail Pharmacy
  - 5.1.7.6.3. Online Pharmacy
- 5.1.8. Canada
- 5.1.9. Mexico

All segments will be provided for all regions and countries covered

5.2. Europe
- 5.2.1. Germany
- 5.2.2. France
- 5.2.3. Italy
- 5.2.4. United Kingdom
- 5.2.5. Russia
- 5.2.6. Netherlands
- 5.2.7. Spain
- 5.2.8. Turkey
- 5.2.9. Poland
5.3. Asia-Pacific
- 5.3.1. India
- 5.3.2. China
- 5.3.3. Japan
- 5.3.4. Australia
- 5.3.5. Vietnam
- 5.3.6. South Korea
- 5.3.7. Indonesia
- 5.3.8. Philippines
5.4. South America
- 5.4.1. Brazil
- 5.4.2. Argentina
5.5. Middle East & Africa
- 5.5.1. Saudi Arabia
- 5.5.2. UAE
- 5.5.3. South Africa

6. Market Mapping, 2023

6.1. By Drug
6.2. By Therapy
6.3. By Indication
6.4. By End-user
6.5. By Distribution Channel
6.6. By Region

7. Macro Environment and Industry Structure

7.1. Supply Demand Analysis
7.2. Import Export Analysis
7.3. Value Chain Analysis
7.4. PESTEL Analysis
- 7.4.1. Political Factors
- 7.4.2. Economic System
- 7.4.3. Social Implications
- 7.4.4. Technological Advancements
- 7.4.5. Environmental Impacts
- 7.4.6. Legal Compliances and Regulatory Policies (Statutory Bodies Included)
7.5. Porter's Five Forces Analysis
- 7.5.1. Supplier Power
- 7.5.2. Buyer Power
- 7.5.3. Substitution Threat
- 7.5.4. Threat from New Entrant
- 7.5.5. Competitive Rivalry

8. Market Dynamics

8.1. Growth Drivers
8.2. Growth Inhibitors (Challenges and Restraints)

9. Regulatory Framework and Innovation

9.1. Patent Landscape
9.2. Regulatory Approvals
9.3. Innovations/Emerging Technologies

10. Key Players Landscape

10.1. Competition Matrix of Top Five Market Leaders
10.2. Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
10.3. Mergers and Acquisitions/Joint Ventures (If Applicable)
10.4. SWOT Analysis (For Five Market Players)
10.5. Patent Analysis (If Applicable)

11. Pricing Analysis

12. Case Studies

13. Key Players Outlook

13.1. Pfizer, Inc.
- 13.1.1. Company Details
- 13.1.2. Key Management Personnel
- 13.1.3. Products & Services
- 13.1.4. Financials (As reported)
- 13.1.5. Key Market Focus & Geographical Presence
- 13.1.6. Recent Developments
13.2. F. Hoffmann-La Roche Ltd.
13.3. Bayer AG
13.4. Bristol-Myers Squibb Company
13.5. Novartis AG
13.6. Johnson & Johnson Inc.
13.7. Dr. Reddy's Laboratories Ltd.
13.8. Amgen Inc.
13.9. EpicentRx, Inc.
13.10. Siemens Healthineer

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work

脳腫瘍の世界市場の評価：薬剤・治療法・適応症・エンドユーザー・流通チャネル・地域別の機会および予測 (2017～2031年)

Brain Cancer Market Assessment, By Drug, By Therapy, By Indication, By End-user, By Distribution Channel, By Region, Opportunities and Forecast, 2017-2031F

目次

第1章調査手法

第2章プロジェクトの範囲と定義

第3章エグゼクティブサマリー

第4章世界の脳腫瘍市場の展望

第5章世界の脳腫瘍市場の展望：地域別

第6章市場マッピング

第7章マクロ環境と産業構造

第8章市場力学

第9章規制の枠組みとイノベーション

第10章主要企業の情勢

第11章価格分析

第12章ケーススタディ

第13章主要企業の見通し

第14章戦略的提言

第15章当社について・免責事項

List of Tables

List of Figures

Table of Contents

1. Research Methodology

2. Project Scope & Definitions

3. Executive Summary

4. Global Brain Cancer Market Outlook, 2017-2031F

5. Global Brain Cancer Market Outlook, By Region, 2017-2031F

6. Market Mapping, 2023

7. Macro Environment and Industry Structure

8. Market Dynamics

9. Regulatory Framework and Innovation

10. Key Players Landscape

11. Pricing Analysis

12. Case Studies

13. Key Players Outlook

14. Strategic Recommendations

15. About Us & Disclaimer

脳腫瘍の世界市場の評価：薬剤・治療法・適応症・エンドユーザー・流通チャネル・地域別の機会および予測 (2017～2031年)

Brain Cancer Market Assessment, By Drug, By Therapy, By Indication, By End-user, By Distribution Channel, By Region, Opportunities and Forecast, 2017-2031F

目次

第1章 調査手法

第2章 プロジェクトの範囲と定義

第3章 エグゼクティブサマリー

第4章 世界の脳腫瘍市場の展望

第5章 世界の脳腫瘍市場の展望：地域別

第6章 市場マッピング

第7章 マクロ環境と産業構造

第8章 市場力学

第9章 規制の枠組みとイノベーション

第10章 主要企業の情勢

第11章 価格分析

第12章 ケーススタディ

第13章 主要企業の見通し

第14章 戦略的提言

第15章 当社について・免責事項

List of Tables

List of Figures

Table of Contents

1. Research Methodology

2. Project Scope & Definitions

3. Executive Summary

4. Global Brain Cancer Market Outlook, 2017-2031F

5. Global Brain Cancer Market Outlook, By Region, 2017-2031F

6. Market Mapping, 2023

7. Macro Environment and Industry Structure

8. Market Dynamics

9. Regulatory Framework and Innovation

10. Key Players Landscape

11. Pricing Analysis

12. Case Studies

13. Key Players Outlook

14. Strategic Recommendations

15. About Us & Disclaimer

第1章調査手法

第2章プロジェクトの範囲と定義

第3章エグゼクティブサマリー

第4章世界の脳腫瘍市場の展望

第5章世界の脳腫瘍市場の展望：地域別

第6章市場マッピング

第7章マクロ環境と産業構造

第8章市場力学

第9章規制の枠組みとイノベーション

第10章主要企業の情勢

第11章価格分析

第12章ケーススタディ

第13章主要企業の見通し

第14章戦略的提言

第15章当社について・免責事項